{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:20:42Z","timestamp":1791328842111,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.amjmed.2006.03.038","type":"journal-article","created":{"date-parts":[[2006,10,28]],"date-time":"2006-10-28T07:18:00Z","timestamp":1162019880000},"page":"912-919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease"],"prefix":"10.1016","volume":"119","author":[{"given":"Murray","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2006.03.038_bib1","first-page":"1","article-title":"On the biochemical mechanism of action of aldosterone","volume":"24","author":"Edelman","year":"1968","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.amjmed.2006.03.038_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/07435808909039097","article-title":"Mechanisms of action of mineralocorticoid hormones","volume":"15","author":"Rossier","year":"1989","journal-title":"Endocr Res"},{"key":"10.1016\/j.amjmed.2006.03.038_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2004.05.004","article-title":"Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy","volume":"96","author":"Tan","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","article-title":"Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift","volume":"19","author":"Epstein","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"24","author":"Hostetter","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HDX.0000061698.20666.aa","article-title":"Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra)","volume":"5","author":"Stier","year":"2003","journal-title":"Heart Dis"},{"key":"10.1016\/j.amjmed.2006.03.038_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11906-000-0017-z","article-title":"Aldosterone and vascular damage","volume":"2","author":"Duprez","year":"2000","journal-title":"Curr Hypertens Rep"},{"issue":"suppl N","key":"10.1016\/j.amjmed.2006.03.038_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/16.suppl_N.92","article-title":"Aldosterone: intracellular receptors in human heart","volume":"16","author":"Bonvalet","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2006.03.038_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajh\/7.1.100","article-title":"Colocalization of 11\u03b2-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells","volume":"7","author":"Kornel","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2006.03.038_bib11","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2006.03.038_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diab.43.1.95","article-title":"Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen","volume":"43","author":"Wakisaka","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2006.03.038_bib13","first-page":"285","article-title":"Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift","volume":"3","author":"Epstein","year":"2004","journal-title":"NephSAP"},{"key":"10.1016\/j.amjmed.2006.03.038_bib14","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjmed.2006.03.038_bib15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib17","first-page":"400A","article-title":"Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone SHR","volume":"110","author":"Stier","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1139\/y85-250","article-title":"Effect of aldosterone on vascular angiotensin II receptors in the rat","volume":"63","author":"Schiffrin","year":"1985","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1053\/snep.2002.34725","article-title":"The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease","volume":"22","author":"Brown","year":"2002","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ki.1992.45","article-title":"Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level","volume":"41","author":"Quan","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.RES.36.2.300","article-title":"Malignant hypertension resulting from deoxycortisone acetate and salt excess: role of renin and sodium in vascular changes","volume":"36","author":"Gavras","year":"1975","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2006.03.038_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib24","first-page":"598","article-title":"Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats","volume":"32","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2006.03.038_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib27","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriolopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.amjmed.2006.03.038_bib28","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000077396","article-title":"Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model","volume":"24","author":"Zhou","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib31","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjmed.2006.03.038_bib34","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2006.03.038_bib35","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","article-title":"Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study","volume":"46","author":"Bianchi","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjmed.2006.03.038_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ki.1987.62","article-title":"Reversing glomerular hypertension stabilizes established glomerular injury","volume":"31","author":"Meyer","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib40","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2006.03.038_bib41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2006.03.038_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib43","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II\u2014renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: a randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2006.03.038_bib45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib46","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjmed.2006.03.038_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2006.03.038_bib48","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjmed.2006.03.038_bib49","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2006.03.038_bib50","first-page":"1075","article-title":"Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension","volume":"33","author":"Epstein","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjmed.2006.03.038_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2006.03.038_bib53","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1681\/ASN.V641134","article-title":"Hyperkalemia in end-stage renal disease: mechanisms and management","volume":"6","author":"Allon","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjmed.2006.03.038_bib54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2006.03.038_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjmed.2006.03.038_bib56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1524-6175.2002.01510.x","article-title":"Eplerenone: a new aldosterone receptor antagonist\u2014are the FDA\u2019s restrictions appropriate?","volume":"5","author":"Sica","year":"2002","journal-title":"J Clin Hypertens"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934306005742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934306005742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:43:50Z","timestamp":1757580230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934306005742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0002934306005742"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2006.03.038","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2006.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}